Sickle Cell Disease Pipeline Analysis 2023 (Updates) | Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Market by DelveInsight

According to DelveInsight's evaluation, there are over 40 key companies globally engaged in the development of more than 50+ Sickle Cell Disease treatment therapies.

DelveInsight's report, titled "Sickle Cell Disease Pipeline Insight, 2023," provides a detailed analysis of clinical trials, therapies, mechanisms of action, route of administration, and developments related to Sickle Cell Disease.

The Sickle Cell Disease pipeline report comprehensively assesses the commercial and clinical aspects of pipeline products, ranging from pre-clinical development to the marketed phase. It includes detailed descriptions of the Sickle Cell Disease drugs, including their mechanisms of action, clinical studies, NDA approvals (if any), and product development activities such as technology, collaborations, mergers, acquisitions, funding, designations, and other relevant details.

Download Sample PDF Report to know more about Sickle Cell Disease drugs and therapies: https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts from the Sickle Cell Disease Pipeline Report include:
1. Companies worldwide are actively working on developing innovative Sickle Cell Disease treatment therapies, with significant success over the years.
2. Leading Sickle Cell Disease companies in the treatment market, such as Sana Biotechnology, Beam Therapeutics, Pfizer, CSL Behring, Novartis, Graphite Bio, Sangamo Therapeutics, Forma therapeutics, Agios Pharmaceuticals, Global Blood Therapeutics, Inc., Vertex Pharmaceuticals, and others, are involved in the development of Sickle Cell Disease therapies.
3. Promising Sickle Cell Disease therapies like SG418, BEAM-102, PF-07209326, CSL889, OTQ923, GPH101, BIVV003, Etavopivat, Mitapivat, Inclacumab, CTX001, and others are expected to have a significant impact on the Sickle Cell Disease market in the coming years.
4. In May 2022, Vertex Pharmaceuticals initiated a study in collaboration with CRISPR Therapeutics to evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001) in pediatric participants with severe Sickle Cell Disease and hydroxyurea (HU) failure or intolerance.
5. In September 2022, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the US Food and Drug Administration (FDA) granted exagamglogeneautotemcel (exa-cel) a rolling review for the potential treatment of Sickle Cell Disease and transfusion-dependent beta thalassemia (TDT).
6. In September 2020, CRISPR Therapeutics and Vertex Pharmaceuticals received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of severe Sickle Cell Disease.

Sickle Cell Disease Overview
Sickle Cell Disease (SCD) is an inherited group of red blood cell disorders characterized by abnormal hemoglobin, resulting in the formation of sickle-shaped cells. These cells are fragile and prone to premature destruction, leading to anemia and various complications. Sickle Cell Disease affects the oxygen-carrying capacity of the blood, resulting in pain episodes, organ damage, and increased susceptibility to infections. It is a chronic condition that primarily affects individuals of African, Mediterranean, Middle Eastern, and Indian descent. Management of Sickle Cell Disease involves supportive care, pain management, blood transfusions, and potentially curative treatments such as hematopoietic stem cell transplantation and emerging Sickle Cell Disease gene therapies.

Download Sample PDF Report to know more@ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:
• SG418: Sana Biotechnology
• BEAM-102: Beam Therapeutics
• PF-07209326: Pfizer
• CSL889: CSL Behring
• OTQ923: Novartis
• BPX-501 T cells: Bellicum Pharmaceuticals
• GPH101: Graphite Bio
• Canakinumab: Novartis
• BIVV003: Sangamo Therapeutics
• EPI01: Novo Nordisk
• Etavopivat: Forma therapeutics
• Mitapivat: Agios Pharmaceuticals
• Inclacumab: Global Blood Therapeutics, Inc.
• CTX001: Vertex Pharmaceuticals

Sickle Cell Disease Route of Administration
Sickle Cell Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Download Sample PDF Report to know more @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sickle Cell Disease Molecule Type
Sickle Cell Disease Products have been categorized under various Molecule types, such as
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Sickle Cell Disease Pipeline Therapeutics Assessment
• Sickle Cell Disease Assessment by Product Type
• Sickle Cell Disease By Stage and Product Type
• Sickle Cell Disease Assessment by Route of Administration
• Sickle Cell Disease By Stage and Route of Administration
• Sickle Cell Disease Assessment by Molecule Type
• Sickle Cell Disease by Stage and Molecule Type

DelveInsight's Sickle Cell Disease Pipeline Report covers around 50+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sickle Cell Disease product details are provided in the report. Download the Sickle Cell Disease pipeline report to learn more about the emerging Sickle Cell Disease therapies @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sickle Cell Disease Pipeline Market Drivers
Increasing prevalence, rising demand for better treatment, and growing health awareness are some of the important factors that are fueling the Sickle Cell Disease Market.

Sickle Cell Disease Pipeline Market Barriers
High cost of treatment, lack of FDA approved treatment and other factors are creating obstacles in the Sickle Cell Disease Market growth.

Scope of Sickle Cell Disease Pipeline Drug Insight
• Coverage: Global
• Key Sickle Cell Disease Companies: Sana Biotechnology, Beam Therapeutics, Pfizer, CSL Behring, Novartis, Graphite Bio, Sangamo Therapeutics, Forma therapeutics, Agios Pharmaceuticals, Global Blood Therapeutics, Inc., Vertex Pharmaceuticals, and others
• Key Sickle Cell Disease Therapies: SG418, BEAM-102, PF-07209326, CSL889, OTQ923, GPH101, BIVV003, Etavopivat, Mitapivat, Inclacumab, CTX001, and others
• Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies
• Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers

Request for Sample PDF Report for Sickle Cell Disease Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Sickle Cell Disease Report Introduction
2. Sickle Cell Disease Executive Summary
3. Sickle Cell Disease Overview
4. Sickle Cell Disease- Analytical Perspective In-depth Commercial Assessment
5. Sickle Cell Disease Pipeline Therapeutics
6. Sickle Cell Disease Late Stage Products (Phase II/III)
7. Sickle Cell Disease Mid Stage Products (Phase II)
8. Sickle Cell Disease Early Stage Products (Phase I)
9. Sickle Cell Disease Preclinical Stage Products
10. Sickle Cell Disease Therapeutics Assessment
11. Sickle Cell Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sickle Cell Disease Key Companies
14. Sickle Cell Disease Key Products
15. Sickle Cell Disease Unmet Needs
16 . Sickle Cell Disease Market Drivers and Barriers
17. Sickle Cell Disease Future Perspectives and Conclusion
18. Sickle Cell Disease Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Bronchial Spasm Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Buerger's Disease Pipeline Insight: https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market

Contact Us:

Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.